Literature DB >> 27151281

Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis.

Michael Hölzel1, Thomas Tüting2.   

Abstract

Phenotype switching contributes to nongenomic heterogeneity in melanoma and other cancers. These dynamic and in part reversible phenotype changes impose diagnostic and therapeutic challenges. Understanding the reciprocal coevolution of melanoma and immune cell phenotypes during disease progression and in response to therapy is a prerequisite to improve current treatment strategies. Here we discuss how proinflammatory signals promote melanoma cell plasticity and govern interactions of melanoma and immune cells in the tumor microenvironment. We examine phenotypic plasticity and heterogeneity in different melanoma mouse models with respect to their utility for translational research and emphasize the interplay between melanoma cells and neutrophils as a critical driver of metastasis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  inflammation; melanoma; metastasis; neutrophils; plasticity; resistance

Mesh:

Substances:

Year:  2016        PMID: 27151281     DOI: 10.1016/j.it.2016.03.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  21 in total

1.  Identification of melanoma cells: a method based in mean variance of signatures via spectral densities.

Authors:  Esperanza Guerra-Rosas; Josué Álvarez-Borrego; Aracely Angulo-Molina
Journal:  Biomed Opt Express       Date:  2017-03-15       Impact factor: 3.732

2.  SMAD signaling promotes melanoma metastasis independently of phenotype switching.

Authors:  Eylul Tuncer; Raquel R Calçada; Daniel Zingg; Sandra Varum; Phil Cheng; Sandra N Freiberger; Chu-Xia Deng; Ingo Kleiter; Mitchell P Levesque; Reinhard Dummer; Lukas Sommer
Journal:  J Clin Invest       Date:  2019-04-30       Impact factor: 14.808

3.  Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials.

Authors:  João Paulo Portela Catani; Rachel P Riechelmann; Sandy Adjemian; Bryan E Strauss
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 3.452

4.  Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies.

Authors:  Sabrina Cappello; Hsu-Min Sung; Christian Ickes; Christine S Gibhardt; Adina Vultur; Hilal Bhat; Zhongwen Hu; Patricia Brafford; Andreas Denger; Ioana Stejerean-Todoran; Rixa-Mareike Köhn; Verena Lorenz; Nicolas Künzel; Gabriela Salinas; Hedwig Stanisz; Tobias Legler; Peter Rehling; Michael P Schön; Karl S Lang; Volkhard Helms; Meenhard Herlyn; Markus Hoth; Carsten Kummerow; Ivan Bogeski
Journal:  Cancer Res       Date:  2021-09-13       Impact factor: 12.701

5.  Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Authors:  Arnav Mehta; Yeon Joo Kim; Lidia Robert; Jennifer Tsoi; Begoña Comin-Anduix; Beata Berent-Maoz; Alistair J Cochran; James S Economou; Paul C Tumeh; Cristina Puig-Saus; Antoni Ribas
Journal:  Cancer Discov       Date:  2018-06-13       Impact factor: 39.397

6.  An omega-3 polyunsaturated fatty acid derivative, 18-HEPE, protects against CXCR4-associated melanoma metastasis.

Authors:  Jieping Li; Chih-Yu Chen; Makoto Arita; Kuijin Kim; Xiangyong Li; Hongman Zhang; Jing X Kang
Journal:  Carcinogenesis       Date:  2018-12-13       Impact factor: 4.944

7.  Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapy.

Authors:  Yeon Joo Kim; Katherine M Sheu; Jennifer Tsoi; Gabriel Abril-Rodriguez; Egmidio Medina; Catherine S Grasso; Davis Y Torrejon; Ameya S Champhekar; Kevin Litchfield; Charles Swanton; Daniel E Speiser; Philip O Scumpia; Alexander Hoffmann; Thomas G Graeber; Cristina Puig-Saus; Antoni Ribas
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

Review 8.  Melanoma models for the next generation of therapies.

Authors:  E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino
Journal:  Cancer Cell       Date:  2021-02-04       Impact factor: 31.743

9.  Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.

Authors:  Isak W Tengesdal; Dinoop R Menon; Douglas G Osborne; Charles P Neff; Nicholas E Powers; Fabia Gamboni; Adolfo G Mauro; Angelo D'Alessandro; Davide Stefanoni; Morkos A Henen; Taylor S Mills; Dennis M De Graaf; Tania Azam; Beat Vogeli; Brent E Palmer; Eric M Pietras; James DeGregori; Aik-Choon Tan; Leo A B Joosten; Mayumi Fujita; Charles A Dinarello; Carlo Marchetti
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-09       Impact factor: 11.205

10.  Melanoma Cell State-Specific Responses to TNFα.

Authors:  Su Yin Lim; Sara Alavi; Zizhen Ming; Elena Shklovskaya; Carina Fung; Ashleigh Stewart; Helen Rizos
Journal:  Biomedicines       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.